Ovarian

BGOG-ov-50

Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 200kHz) concomitant with weekly paclitaxel for the treatment of platinum-resistant ovarian cancer (PROC)

Sponsor: Novocure

Participating sites:

  • CHU UCL Namur, site Sainte Elisabeth, Namur
  • UZ Gent, Gent
  • UZ Leuven, Leuven
  • CHU Ambroise Paré, Mons
  • AZ Maria Middelares, Gent
  • CHU Dinant Godinne, Yvoir
  • Grand Hôpital de Charleroi, Charleroi
  • Imelda ziekenhuis, Bonheiden
  • CHU UCL St-Luc, Bruxelles

Learn More ->

BGOG-ov-46

Phase III Randomised, Double Blind, Placebo Controlled, Multicentre Study of durvalumab in combination with chemotherapy and bevacizumab followed by maintenance durvalumab, bevacizumab and olaparib in newly diagnosed advanced ovarian cancer patients

Sponsor: AstraZeneca

Participating sites:

  • AZ Nikolaas, St-Niklaas
  • AZ Damiaan, Oostende
  • OLV Aalst, Aalst
  • UZ Leuven, Leuven
  • CHU UCL Namur, site Sainte Elisabeth, Namur

Learn More ->

BGOG-ov-44

A Randomized, Double-Blind, Phase 3 Comparison of Platinum-Based Therapy with TSR-042 and Niraparib Versus Standard of Care Platinum-Based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer

Sponsor: GSK/Tesaro

Participating sites:

  • UZ Leuven, Leuven
  • AZ Sint-Jan Brugge, Brugge
  • CHU St. Pierre, Bruxelles
  • AZ Klina, Brasschaat

Learn More ->

BGOG-ov-43

A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the FirstLine Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer (EOC)

Sponsor: Merck Sharp & Dohme Corp.

Participating sites:

  • AZ Maria Middelares, Gent
  • Imelda Ziekenhuis, Bonheiden
  • Grand Hôpital de Charleroi, Charleroi
  • Hôpital de Libramont, Libramont
  • UZ Leuven, Leuven
  • UZ Gent, Gent
  • Jessa Ziekenhuis, Hasselt
  • CHU de Liège, site Sart Tilman, Liège
  • UZ Antwerpen, Antwerpen
  • CHU UCL St-Luc, Bruxelles

Learn More ->

BGOG-ov-41

A phase III randomized, double-blinded trial of platinum-based chemotherapy with or without atezolizumab followed by niraparib maintenance with or without atezolizumab in patients with recurrent ovarian, tubal or peritoneal cancer and platinum treatment-free interval (TFIp) >6 months

Sponsor: Grupo Español de Investigación en Cáncer de Ovario (GEICO)

Participating sites:

  • UZ Leuven, Leuven
  • CHU Ambroise Paré, Mons
  • CHU UCL Namur, site Sainte Elisabeth, Namur
  • CHU UCL St. Luc, Bruxelles
  • Grand Hôpital de Charleroi, Charleroi
  • CHU de Liège, site Sart Tilman, Liège

Learn More ->

BGOG-ov-55

MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator’s Choice of Chemotherapy in Advanced High Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression

Sponsor: ImmunoGen

Participating sites:

  • Hôpital de Libramont, Libramont
  • UZ Leuven, Leuven
  • OLV Aalst, Aalst
  • UZ Antwerpen, Antwerpen
  • AZ Sint Lucas, Gent
  • AZ Klina, Roeselare

Learn More ->

BGOG-ov-38

A Phase IIIb, Randomised, Double-blind, Placebo-controlled, Multicentre Study of Olaparib Maintenance Retreatment in Patients with Epithelial Ovarian Cancer Previously Treated With a PARPi and Responding to Repeat Platinum Chemotherapy.

Learn More ->